Arbutus Biopharma (ABUS) Change in Accured Expenses (2013 - 2026)

Arbutus Biopharma has disclosed Change in Accured Expenses across 14 years of filings, most recently posting -$985000.0 for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$985000.0, down 121.67% year-over-year; the trailing twelve-month figure through Mar 2026 was -$7.6 million (down 224.37% YoY), and the FY2025 annual result was -$2.1 million, down 389.53% from the prior year.
• Change in Accured Expenses came in at -$985000.0 for Q1 2026 at Arbutus Biopharma, down from $806000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $4.5 million in Q1 2025 to a low of -$7.6 million in Q2 2025.
• The 5-year median for Change in Accured Expenses is -$124000.0 (2022), against an average of -$257000.0.
• Peak annual rise in Change in Accured Expenses reached 2667.12% in 2024, while the deepest fall reached 2635.14% in 2024.
• Arbutus Biopharma's Change in Accured Expenses stood at -$124000.0 in 2022, then declined by 25.0% to -$155000.0 in 2023, then grew by 20.0% to -$124000.0 in 2024, then soared by 750.0% to $806000.0 in 2025, then plunged by 222.21% to -$985000.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$985000.0 (Q1 2026), $806000.0 (Q4 2025), and $145000.0 (Q3 2025), per Business Quant data.